In conclusion, the monoclonal antibodies used in this study may be useful for diagnostic purposes when a suspicious looking infiltration is detected by CE. However, these antibodies could not detect metastatic tumour cells in the bone marrow sections from patients in whom CE did not reveal any tumour cells.
Bone marrow metastases (BMM) are common in patients with Small Cell Lung Cancer (SCLC). At the time of the primary diagnosis, BMM are detected in approximately 25% of the patients by conventional histologic examination (CE) (Hirsch et al., 1977; Hirsch & Hansen, 1980) , including H&E stained sections of needle biopsies, aspiration clots and aspirate smears from the iliac crest. The finding of BMM may be of prognostic and therapeutic relevance (Hirsch & Hansen, 1980) . Using various monoclonal antibodies (Mabs) a number of groups have identified isolated carcinoma cells (presumed micrometastases) in the bone marrow that were not detected by CE (Stahel et al., 1985; Hay et al., 1988; Leonard et al., 1990; Trillet et al., 1989; Cote et al., 1988) . In some of the studies this finding was found to be of prognostic significance (Leonard et al., 1990) . Thus, it appears that routine cytological and histopathological examination of bone marrow may underestimate the rate of BMM in SCLC, which may be of significance for the clinical management of patients with SCLC.
In the present study we investigated the usefulness of a panel of 7 Mabs, included in the panel of antibodies tested at the International Workshop on Small Cell Lung Cancer (Souhami et al., 1987) , for detecting of BMM in patients newly diagnosed with SCLC and compared the results with CE of the bone marrow. For evaluation of the specificity of the antibodies, a control group of patients with nonmalignant disease who underwent bone marrow examination was studied. Table I ). The primary antibodies were applied for 30 min, and a standard three step PAP (peroxidase-anti-peroxidase) technique was used. The peroxidase activity was detected by incubation in ethylcarbazole for 10 min, and a light counterstain was given by 3 min in Mayers Haematoxylin. As a negative control the primary antibody was omitted, but otherwise the same procedure was used.
Materials and methods

Patients
Evaluation
The immunostaining was assessed by one observer (B.G.S. (Kaplan & Meier, 1958) . Statistical significance was assumed when P was less than 0.05. Analysis of agreement between CE and immunohistochemistry was performed by the Kappa method (Cohen, 1960) . Finally, the bone marrow aspiration clots from 20 pts without malignant disease were examined. In each of the aspiration clots there were at least ten areas of haemopoetic cells available for diagnosis.
Results
Characteristic ofpts with SCLC The clinical and pathological characteristics of the patients at the time of primary diagnosis are shown in Table II . The significant difference in dissemination of the disease and the levels of serum LDH in the two groups of pts are in agreement with previous studies (Sagman et al., 1991) .
The mean survival time for pts without BMM both by CE and Mabs was 439 days vs 202 days for pts with BMM (P<0.001) (Figure 1) .
Staining of the primary tumours by Mabs
The results of the staining of the primary tumours from pts with and without BMM by CE are shown in Table III shown in Table IV 
Discussion
Where metastatic tumour cells are present in bone marrow from patients with SCLC we have previously reported a high proportion of positive tumour cells when using the same panel of antibodies as in the present study (Skov et al., 1991 Re (1): The antibodies applied in the present study have previously been tested during the SCLC workshops (Souhami et al., 1987) marrow aspiration smears from 28 pts with SCLC and from an unknown number of patients with folate deficiency. Two of those Mabs, CAM 5.2 and HMFG 2, which were used in the present study too, did not significantly increase the detection rate of BMM compared to CE, whereas using a panel of five other Mabs, including neural associated antibodies (123A8, UJ 13A), did increase the detection of positive tumour cells in 75% of the samples. Less than 1% of the normal marrow cells were positive. In another study from the same group (Leonard et al., 1990) , the same panel of Mabs was applied on bone marrow smears from 12 pts with no BMM by CE. In eight of these pts positive tumour cells were detected. It was stated that any known cross-reactivity with control marrows was taken into account before SCLC patients marrows were reported as positive or negative. Stahel et al. (1985) , used a Mab reactive with the surface membrane of SCLC cells, SM 1, and tumour cells were detected in 69% of bone marrow smears compared to only 16% by CE of bilateral bone marrow examination from 33 patients. Using UJ 13A and an immunofluorescence detection method on bone marrow aspiration smears, another group detected positive tumour cells in 4/26 patients with negative CE. No controls were included (Trillet et al., 1989) .
Thus, Mabs -especially those detecting neuroendocrine antigens -may be of value for detecting micrometastases not identified by CE. However, unfortunately, most of these Mabs are not useful on fixed tissue. In all the above mentioned studies cytological material was used. Bone marrow aspiration smears have in some studies been shown to be of more diagnostic value than bone marrow biopsies in detecting metastases from SCLC by CE (Hirsch et al., 1977) .
In the present study no unfixed tissue and no unstained smears were available for immunohistochemistry. However, the aim of the present study was to compare the results of CE of bone marrow aspiration clots to those obtained with immunohistochemical detection of SCLC cells in the same aspiration clots, in order to determine if the same (high) proportion of tumour-positive marrows were detected as by the cytological examination. Furthermore, compared with other studies, we have used different Mabs and the technical procedures were not the same in these studies.
Our results may be contingent on one of two possibilities: (1) There were infact no metastatic tumour cells in the bone marrow specimens, and (2) the method used in the present study were not sensitive enough to detect tumour cells actually present in the bone marrow specimens. How can the true diagnosis be established? Assessment of the reliability of a diagnostic procedure is important. In the present study we could have used another paraclinical examination, i.e. bone marrow scanning as a diagnostic tool. Unfortunately, the results of this examination are often difficult to interpret, the method is too insensitive to detect minimal metastases because it depends on the destruction of bone matrix, and the diagnosis 'BMM' has not been defined with relation to this procedure. The clinical course of the disease is not useful as BMM at autopsy may have developed during the time of observation. Even an in vitro test has been used as a diagnostic tool. In such a test, the model must imitate all the physiologic conditions in the human which may influence the results of what we wish to determine. Thus, it may be difficult in a meaningful way to determine the accuracy of a diagnostic method in a representative, random sample of pts. As suggested by Wulff (1982) , perhaps one should forget the question of the truth of a diagnostic method and only be interested in the implication of the decision that is made on the basis of the diagnostic result.
In the present study, pts without detectable tumour cells in bone marrow by both CE and immunohistochemistry had a significantly longer survival than pts with BMM. No differences in these two groups were observed according to age, sex and performance status (Table II) . Hirsch and Hansen (1980) reported that pts with histologically verified BMM had a significantly shorter survival than pts with advanced disease but without bone marrow metastases. If tumour cells had been overlooked in the marrows in the present study one would have expected the same (short) survival in both groups of patients. As immunohistochemistry does not detect tumour cells that are not identified by CE, the two curves are identical (Figure 1) , and this supports the value of both methods.
Although the Mabs used in this study failed to detect metastatic tumour cells in bone marrow sections where CE has not revealed any tumour cells, these Mabs may be useful for confirmatory diagnostic purposes when a suspicious infiltration is detected by CE.
